BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11561689)

  • 1. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.
    George CM; Haraf DJ; Mauer AM; Krauss SA; Hoffman PC; Rudin CM; Szeto L; Vokes EE
    Invest New Drugs; 2001; 19(4):303-10. PubMed ID: 11561689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of docetaxel with concomitant thoracic radiation therapy.
    Mauer AM; Masters GA; Haraf DJ; Hoffman PC; Watson SM; Golomb HM; Vokes EE
    J Clin Oncol; 1998 Jan; 16(1):159-64. PubMed ID: 9440738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
    Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
    Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer.
    Choy H; Akerley W; Safran H; Clark J; Rege V; Papa A; Glantz M; Puthawala Y; Soderberg C; Leone L
    J Clin Oncol; 1994 Dec; 12(12):2682-6. PubMed ID: 7989944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
    Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
    J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H; Yee L; Cole BF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
    Hirao M; Fujitani K; Tsujinaka T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):53-6. PubMed ID: 15675582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer.
    Schild SE; McGinnis WL; Graham D; Hillman S; Fitch TR; Northfelt D; Garces YI; Shahidi H; Tschetter LK; Schaefer PL; Adjei A; Jett J
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1106-11. PubMed ID: 16730134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
    Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
    Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E; de Vries EG; Meijer S; Groen HJ
    Cancer Chemother Pharmacol; 2000; 45(1):89-92. PubMed ID: 10647508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study to determine the MTD of paclitaxel given three times per week during concurrent radiation therapy for stage III non-small cell lung cancer.
    Shi A; An T; Zhu G; Yu R; Xu G; Liu X; Xu B
    Curr Med Res Opin; 2007 May; 23(5):1161-7. PubMed ID: 17519083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
    Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
    Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
    J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.